CORRESP Filing
ADIAL PHARMACEUTICALS, INC.
Date: June 12, 2025 · CIK: 0001513525 · Accession: 0001213900-25-053828
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287826
Letter
VIA EDGAR United States Securities Division of Corporation Finance Attention: Doris Stacy Gama Re: Adial Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed June 6, 2025 File No: 333-287826
Dear Ms. Gama:
Adial Pharmaceuticals, Inc. (the " Registrant ") hereby requests that the effective date of the above-referenced Registration Statement on Form S-1, as amended (File No. 333-287826), be accelerated by the U.S. Securities and Exchange Commission (the " Commission ") to become effective on Monday, June 16, 2025 , at 9:15 a.m ., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Very truly yours,
ADIAL PHARMACEUITCALS, INC.
Show Raw Text
CORRESP 1 filename1.htm June 12, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Doris Stacy Gama Re: Adial Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed June 6, 2025 File No: 333-287826 Dear Ms. Gama: Adial Pharmaceuticals, Inc. (the " Registrant ") hereby requests that the effective date of the above-referenced Registration Statement on Form S-1, as amended (File No. 333-287826), be accelerated by the U.S. Securities and Exchange Commission (the " Commission ") to become effective on Monday, June 16, 2025 , at 9:15 a.m ., Eastern Time, or as soon as reasonably practicable thereafter. The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement. The Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted. Very truly yours, ADIAL PHARMACEUITCALS, INC. By: /s/ Cary Claiborne Name: Cary Claiborne Title: Chief Executive Officer cc: Leslie Marlow, Blank Rome LLP